Meeting
2021 ASCO Annual Meeting
A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.
Authors
Dean Anthony Fennell
University of Leicester and University Hospitals of Leicester, Leicester, United Kingdom
Dean Anthony Fennell , Amy King , Seid Mohammed , Amy Branson , Alastair Greystoke , Sam Moody , Margaret Hutka , Alan G. Dawson , Liz Darlison , Molly Scotland , Vina Bhundia , Amrita Bajaj , Bruno Morgan , Adrian Nicholson , Cassandra Brookes , Aarti Gaba , Peter Wells-Jordan , Catherine Jane Richards , Anne Thomas
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT03654833
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 8558)
DOI
10.1200/JCO.2021.39.15_suppl.8558
Abstract #
8558
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
MiST1: A phase IIa trial of rucaparib in patients harbouring BAP1/BRCA1 deficient relapsed malignant mesothelioma.
First Author: Dean Anthony Fennell
Poster
2018 ASCO Annual Meeting
Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
First Author: Marjorie Glass Zauderer
Poster
2023 ASCO Annual Meeting
A phase II study of olaparib and durvalumab in patients with IDH-mutated cholangiocarcinoma.
First Author: Erica S. Tsang
Poster
2022 ASCO Annual Meeting
Atezolizumab and bevacizumab in patients with relapsed mesothelioma: MIST4—a phase IIa trial with cellular and molecular correlates of efficacy.
First Author: Dean Anthony Fennell